Published in Liver Transpl on June 01, 2007
Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. J Ophthalmic Inflamm Infect (2013) 1.85
Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature. J Transplant (2014) 0.89
Sirolimus associated pneumonitis after nonmyeloablative peripheral blood stem cell transplant for sickle cell disease. Biol Blood Marrow Transplant (2008) 0.86
One-Year Outcomes of the SAVE Study: Sirolimus as a Therapeutic Approach for UVEitis. Transl Vis Sci Technol (2015) 0.80
A Decade of Experience Using mTor Inhibitors in Liver Transplantation. J Transplant (2011) 0.76
Sirolimus induced granulomatous interstitial pneumonitis. Respir Med Case Rep (2012) 0.76
Analysis of factors that affect outcome after transplantation of kidneys donated after cardiac death in the UK: a cohort study. Lancet (2010) 4.72
Banking on human embryonic stem cells: estimating the number of donor cell lines needed for HLA matching. Lancet (2005) 3.73
Effect of donor age and cold storage time on outcome in recipients of kidneys donated after circulatory death in the UK: a cohort study. Lancet (2012) 2.69
B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med (2009) 2.56
Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol (2005) 2.14
Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol (2005) 1.99
Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol (2005) 1.96
Generating an iPSC bank for HLA-matched tissue transplantation based on known donor and recipient HLA types. Cell Stem Cell (2012) 1.75
Evaluation of early abdominopelvic computed tomography in patients with acute abdominal pain of unknown cause: prospective randomised study. BMJ (2002) 1.69
TNFR1- and TNFR2-mediated signaling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J (2005) 1.60
A simplified donor risk index for predicting outcome after deceased donor kidney transplantation. Transplantation (2012) 1.57
Quality of life up to 30 years following liver transplantation. Liver Transpl (2008) 1.57
Electrostatic modifications of the human leukocyte antigen-DR P9 peptide-binding pocket and susceptibility to primary sclerosing cholangitis. Hepatology (2011) 1.51
Predicting HLA class I alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation (2009) 1.49
Advising potential recipients on the use of organs from donors with primary central nervous system tumors. Transplantation (2012) 1.48
Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation. Transplantation (2010) 1.41
Transplantation between monozygotic twins: how identical are they? Transplantation (2014) 1.38
Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol (2010) 1.22
Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant (2005) 1.22
TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol (2008) 1.18
Immunological considerations for embryonic and induced pluripotent stem cell banking. Philos Trans R Soc Lond B Biol Sci (2011) 1.17
Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation. Transplantation (2004) 1.16
Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS Guidelines. Br J Haematol (2010) 1.15
Acute graft versus host disease following liver transplantation: the enemy within. Am J Transplant (2004) 1.14
Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. J Immunol (2012) 1.08
Defining delayed graft function after renal transplantation: simplest is best. Transplantation (2013) 1.06
Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest (2006) 1.05
Factors affecting graft and patient survival after live donor kidney transplantation in the UK. Transplantation (2010) 1.04
Allorecognition pathways in transplant rejection and tolerance. Transplantation (2013) 1.02
The discard of deceased donor kidneys in the UK. Clin Transplant (2014) 1.02
What nephrologists need to know about antiphospholipid syndrome. Nephrol Dial Transplant (2010) 1.02
A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl (2007) 1.02
Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific alloantibodies in renal transplantation. Hum Immunol (2009) 1.00
A New UK 2006 National Kidney Allocation Scheme for deceased heart-beating donor kidneys. Transplantation (2010) 0.98
Summary of the British Transplantation Society/Renal Association U.K. guidelines for living donor kidney transplantation. Transplantation (2012) 0.97
Copresentation of intact and processed MHC alloantigen by recipient dendritic cells enables delivery of linked help to alloreactive CD8 T cells by indirect-pathway CD4 T cells. J Immunol (2013) 0.97
Is the increase in DCD organ donors in the United Kingdom contributing to a decline in DBD donors? Transplantation (2010) 0.97
Expression of silencer of death domains and death-receptor-3 in normal human kidney and in rejecting renal transplants. Am J Pathol (2003) 0.96
Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation (2007) 0.95
Regulation of allograft survival by inhibitory FcγRIIb signaling. J Immunol (2012) 0.94
Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ (2008) 0.93
The development of a modified human IFN-alpha2b linked to the Fc portion of human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J Interferon Cytokine Res (2004) 0.92
A prospective randomized trial comparing 2-octyl cyanoacrylate to conventional suturing in closure of laparoscopic cholecystectomy incisions. J Laparoendosc Adv Surg Tech A (2004) 0.91
Blocking lymphotoxin signaling abrogates the development of ectopic lymphoid tissue within cardiac allografts and inhibits effector antibody responses. FASEB J (2011) 0.91
Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation. Transplantation (2006) 0.91
Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation (2006) 0.91
Early experience of paired living kidney donation in the United kingdom. Transplantation (2008) 0.90
Predicting HLA class II alloantigen immunogenicity from the number and physiochemical properties of amino acid polymorphisms. Transplantation (2011) 0.90
Some observations on prope tolerance. Curr Opin Organ Transplant (2011) 0.89
Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection. Transplantation (2013) 0.89
Indirect allorecognition: not simple but effective. Transplantation (2008) 0.88
OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival. Transplantation (2004) 0.88
Abrogation of antibody-mediated allograft rejection by regulatory CD4 T cells with indirect allospecificity. J Immunol (2007) 0.88
Donor CD4 T cells contribute to cardiac allograft vasculopathy by providing help for autoantibody production. Circ Heart Fail (2009) 0.88
PECAM-1 polymorphism affects monocyte adhesion to endothelial cells. Transplantation (2008) 0.86
Predicting the immunogenicity of human leukocyte antigen class I alloantigens using structural epitope analysis determined by HLAMatchmaker. Transplantation (2008) 0.85
High-resolution, three-dimensional modeling of human leukocyte antigen class I structure and surface electrostatic potential reveals the molecular basis for alloantibody binding epitopes. Hum Immunol (2011) 0.85
A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant (2005) 0.85
Dendritic cells internalise and re-present conformationally intact soluble MHC class I alloantigen for generation of alloantibody. Eur J Immunol (2007) 0.85
The UK scheme for mandatory continuous monitoring of early transplant outcome in all kidney transplant centers. Transplantation (2009) 0.85
Alemtuzumab (CAMPATH-1H) for the treatment of acute rejection in kidney transplant recipients: long-term follow-up. Transplantation (2009) 0.85
Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation (2009) 0.84
Factors influencing outcome after deceased heart beating donor kidney transplantation in the United Kingdom: an evidence base for a new national kidney allocation policy. Transplantation (2010) 0.84
Heterogeneous inflammatory changes in liver graft recipients with normal biochemistry. Transplantation (2010) 0.84
Giant atypical ossifying fibromyxoid tumour of the calf. Skeletal Radiol (2005) 0.84
CMV mismatch does not affect patient and graft survival in UK renal transplant recipients. Transplantation (2009) 0.83
Unlinked memory helper responses promote long-lasting humoral alloimmunity. J Immunol (2012) 0.83
Comparison of allogeneic and xenogeneic in vitro T-cell proliferative responses in sensitized patients awaiting kidney transplantation. Xenotransplantation (2003) 0.82
Buschke-Ollendorff syndrome: a manifestation of a heterozygous nonsense mutation in the LEMD3 gene. J Am Acad Dermatol (2008) 0.82
Current status of renal transplantation. Methods Mol Biol (2006) 0.82
Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients. Transplantation (2005) 0.82
Impact of Cytomegalovirus on Long-term Mortality and Cancer Risk After Organ Transplantation. Transplantation (2015) 0.80
Ventilation-perfusion scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing pneumonectomy. AJR Am J Roentgenol (2006) 0.80
Donor type does not influence the incidence of major urologic complications after kidney transplantation. Transplantation (2010) 0.80
Targeting IL-15 as a therapeutic strategy in organ transplant rejection. Curr Opin Investig Drugs (2002) 0.80
Three-dimensional structural modelling and calculation of electrostatic potentials of HLA Bw4 and Bw6 epitopes to explain the molecular basis for alloantibody binding: toward predicting HLA antigenicity and immunogenicity. Transplantation (2015) 0.80
Linkage of a national clinical liver transplant database with administrative hospital data: methods and validation. Transplantation (2014) 0.80
Detection of pulmonary nodules at paediatric CT: maximum intensity projections and axial source images are complementary. Pediatr Radiol (2013) 0.80
Classification of encapsulating peritoneal sclerosis is important, but must encapsulate the entire spectrum of the disease. Perit Dial Int (2013) 0.79
Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation: A Meta-Analysis of Randomized Controlled Trials. Transplantation (2016) 0.79
Subcutaneous administration of alemtuzumab in simultaneous pancreas-kidney transplantation. Transplantation (2007) 0.79
Analysis of ischemia/reperfusion injury in time-zero biopsies predicts liver allograft outcomes. Liver Transpl (2015) 0.79
Use of quantitative lung scintigraphy to predict postoperative pulmonary function in lung cancer patients undergoing lobectomy. Ann Thorac Surg (2004) 0.78
Late outgrowth endothelial progenitor cells engineered for improved survival and maintenance of function in transplant-related injury. Transpl Int (2011) 0.78
Sensitisation to swine leukocyte antigens in patients with broadly reactive HLA specific antibodies. Am J Transplant (2002) 0.78
Recipients who receive a human leukocyte antigen-B compatible cadaveric liver allograft are at high risk of developing acute graft-versus-host disease. Transplantation (2004) 0.78
Factors associated with Short and Long Term Liver Graft Survival in the United Kingdom: Development of a UK Donor Liver Index. Transplantation (2016) 0.77
A roundabout route to rejection: the contribution of cross-primed CD8 T cells. Am J Transplant (2004) 0.77
Versatile and enhanced tumour modelling in mice via somatic cell transduction. J Pathol (2014) 0.77
Current practices of donor pancreas allocation in the UK: future implications for pancreas and islet transplantation. Transpl Int (2005) 0.77
Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome. J Heart Lung Transplant (2009) 0.76